FREE WEBINAR!! Enhancing Patient Safety: Overview of the INS 2024 Non-Antineoplastic Vesicant List and Resources
|
|
Stay ahead in patient safety
|
|
|
|
Patient safety is always a priority, and when it comes to the administration of vesicants, there’s much we can do to minimize the risk of tissue injury. Join us on February 20 at 2 p.m. ET for an exclusive webinar titled: “Enhancing Patient Safety: Overview of the INS 2024 Non-Antineoplastic Vesicant List and Resources” with expert Barb Nickel, APRN-CNS, CCRN, CRNI.
In this session, Ms. Nickel will discuss critical aspects of non-antineoplastic vesicants and the latest resources to improve patient care.
What you’ll learn:
- Characteristics of non-antineoplastic vesicants that may cause tissue injury
- Preventative interventions to help reduce the risk of extravasation
- How vesicant resources can be utilized to improve patient outcomes
|
|
|
|
|
|
|
Barb Nickel, APRN-CNS, CCRN, CRNI
|
|
Ms. Nickel is a Clinical Nurse Specialist at a large healthcare system in the US, responsible for staff development and process improvement to optimize outcomes in multiple areas of clinical practice, including critical care, infusion therapy, sepsis, and new graduate transition to practice. Ms. Nickel has presented nationally and published in several peer-reviewed journals on infusion-related topics, was the chair of the 2024 Standards of Practice Committee, and is now chair of the 2027 INS SOP Committee. She also serves as Adjunct Research Fellow for Griffith University, Queensland, Australia.
|
|
|
DATE
|
|
February 20 at 2 p.m. ET
|
|
|
DURATION
|
|
45-minute presentation, followed by a 15-minute live Q&A
|
|
|
|
|
|
Specialties
Acute Care
Anesthesiology
Critical Care
Educational/Research
Emergency/Trauma
Geriatrics
Hematology / Oncology
Home Health
Infection Control / Infectious Disease
Infusion / Vascular
Management/Admin/Leadership
Medical/Surgical
Neonatal
Nursing Student
OB/GYN/L&D
Pediatrics
Perianesthesia
Perioperative
Professional Development
Quality / Risk Management
